Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | GLP1R | P43220 | 4/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.57 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.57 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466813 | 1.00 | TFPI (0.70) | TFPIRXFP1GLP1RGRIN2DGRIN3B | |
| SCHEMBL31242354 | 0.96 | TFPI (0.67) | TFPIRXFP1GLP1RGRIN2DGRIN3B | |
| SCHEMBL29466810 | 0.96 | TFPI (0.67) | TFPIRXFP1GLP1RGRIN2DGRIN3B | |
| SCHEMBL30769537 | 0.96 | TFPI (0.65) | TFPIRXFP1GLP1ROPRL1 | |
| SCHEMBL30900775 | 0.92 | TFPI (0.69) | TFPIRXFP1GLP1RBECN1 | |
| SCHEMBL30900789 | 0.90 | TFPI (0.66) | TFPIGLP1RBECN1 | |
| SCHEMBL30900786 | 0.90 | TFPI (0.66) | TFPIGLP1RBECN1 | |
| SCHEMBL30176422 | 0.89 | GLP1R (0.59) | TFPIGLP1R | |
| SCHEMBL30447212 | 0.89 | TFPI (0.64) | TFPIRXFP1GLP1R | |
| SCHEMBL30950136 | 0.88 | GLP1R (0.65) | TFPIGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TEARSOLUTIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-20250222070-A1 | STABLE PEPTIDE COMPOSITIONS | TEARSOLUTIONS INC (US) | 2025-07-10 | — | — | US | claimed |
| CN-119730839-A | Stable peptide compositions and methods of using the same for treating ocular symptoms associated with moderate/severe dry eye | 缇尔索卢森公司 | 2025-03-28 | — | — | CN | claimed |
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TEARSOLUTIONS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250222070-A1 | STABLE PEPTIDE COMPOSITIONS | TEARSOLUTIONS INC (US) | 2025-07-10 | — | — | US | disclosed |
| CN-119730839-A | Stable peptide compositions and methods of using the same for treating ocular symptoms associated with moderate/severe dry eye | 缇尔索卢森公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-110461350-B | Stabilized peptide compositions | 缇尔索卢森公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-05 | — | — | US | disclosed |
| US-12064469-B2 | Stable peptide compositions | TEARSOLUTIONS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20220305083-A1 | STABLE PEPTIDE COMPOSITIONS | TEARSOLUTIONS INC (US) | 2022-09-29 | — | — | US | disclosed |
| CN-114206916-A | Restricted peptides | 缇尔索卢森公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021159-A1 | STABLE PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MODERATE/SEVERE DRY EYE-RELATED OCULAR SYMPTOMS | TRPC1, TRPC7, ASNS | TFPI 912/4885RXFP1 153/4885GLP1R 76/4885 |
| US-20240294573-A1 | CONSTRAINED PEPTIDES | IAPP, NGLY1, VIP | TFPI 1844/4885RXFP1 198/4885GLP1R 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.